alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 851–875 of 10,985 studies · free to read (page 35 of 440) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study

✓ Peer-reviewed alzhub usefulness score 67 out of 100. BMJ (Clinical research ed.) 2021-09-17

Of 6 952 440 vaccinated patients in the derivation cohort, 5 150 310 (74.1%) had two vaccine doses. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study

✓ Peer-reviewed alzhub usefulness score 67 out of 100. BMJ (Clinical research ed.) 2009-12-22

This large cohort of 85 year olds showed good levels of both self rated health and functional ability despite significant levels of disease and impairment. 4 key findings →

Design: cohort study Participants: 853 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Risk factors and screening instruments to predict adverse outcomes for undifferentiated older emergency department patients: a systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2015-01-01

Studies were significantly heterogeneous in terms of country, outcomes assessed, and the timing of post-ED outcome assessments. 5 key findings →

Design: systematic review Participants: 7,940 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Blood pressure from mid- to late life and risk of incident dementia

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Neurology 2017-11-08

Elevated blood pressure during midlife, persistence of elevated blood pressure into late life, and, among nonhypertensives, a steep decline in blood pressure during mid- to late life were associated with an increased dementia risk in a community-based cohort. 5 key findings →

Participants: 1,440 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discovery

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-06-01

Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. 2 key findings →

Design: cohort study Participants: 1,135 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer's disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Ageing research reviews 2021-10-29

Accumulating evidence demonstrates that metabolic changes in the brain associated with neuroinflammation, oxidative stress, and mitochondrial dysfunction play an important role in the pathophysiology of mild cognitive impairment (MCI) and Alzheimer's disease (AD). 4 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Brain : a journal of neurology 2012-05-23

However, few longitudinal Pittsburgh compound B-positron emission tomography studies have tested this hypothesis, and with conflicting results. 5 key findings →

Design: longitudinal study Participants: 32 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cognitive and memory training in adults at risk of dementia: a systematic review

✓ Peer-reviewed alzhub usefulness score 67 out of 100. BMC geriatrics 2011-09-25

Previous conclusions of a lack of efficacy for cognitive training in MCI may have been influenced by not clearly defining the intervention. 1 key finding →

Design: systematic review Participants: 305 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA neurology 2016-01-01

In persons selected from a population-based study, elevated amyloid levels at baseline were associated with worse cognition and imaging biomarkers at baseline and with greater clinical decline and neurodegeneration. 5 key findings →

Design: longitudinal study Participants: 286 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Parkinsonism & related disorders 2018-02-09

This study provides evidence for sex differences in the progression to cognitive impairment in PD, while specific cognitive features become more important indicators of progression with impending conversion to PDD. 3 key findings →

Design: longitudinal study Participants: 418 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Journal of neurology, neurosurgery, and psychiatry 2011-04-14

The APOE-ε4 allele is associated with a moderately increased risk for progression from MCI to AD-type dementia. 4 key findings →

Design: meta-analysis Participants: 35 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Donepezil delays progression to AD in MCI subjects with depressive symptoms

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Neurology 2009-06-01

Cox proportional hazards regression, adjusted for age at baseline, gender, apolipoprotein genotype, and NYU paragraph delayed recall score, showed that higher BDI scores were associated with progression to AD (p = 0.03). 4 key findings →

Participants: 208 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

TREM2 is associated with increased risk for Alzheimer's disease in African Americans

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Molecular neurodegeneration 2015-04-10

TREM2 encodes for triggering receptor expressed on myeloid cells 2 and has rare, coding variants that associate with risk for late-onset Alzheimer's disease (LOAD) in Caucasians of European and North-American origin. 4 key findings →

Design: case-control study Participants: 800 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Acta neuropathologica 2020-03-12

A rare coding variant (rs72824905, p.P522R) conferring protection against Alzheimer's disease (AD) was identified in the gene encoding the enzyme phospholipase-C-γ2 (PLCG2) that is highly expressed in microglia. 4 key findings →

Design: longitudinal study Participants: 10,097 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging

✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA neurology 2019-11-01

Blood biomarkers able to diagnose Alzheimer disease (AD) at the preclinical stage would enable trial enrollment when the disease is potentially reversible. 4 key findings →

Design: case-control study Participants: 161 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Neurology 2023-10-11

This study included patients with clinical SCD and SCD-free, healthy control (HC) participants with available baseline CSF and/or longitudinal cognitive data from the observational DZNE Longitudinal Cognitive Impairment and Dementia study. 4 key findings →

Design: longitudinal study Participants: 672 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study

✓ Peer-reviewed alzhub usefulness score 67 out of 100. The Lancet. Neurology 2025-11-01

Understanding the neuropathological effects of amyloid β (Aβ)-targeting therapies and amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease is critical for optimising treatment efficacy and patient outcomes. 4 key findings →

Design: case-control study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed